Bispecific ADCs Development

Bispecific ADC (antibody-drug conjugate) technology is revolutionizing targeted cancer therapy by combining the precision of bispecific antibodies with the potency of cytotoxic drugs. Unlike traditional ADCs, bispecific ADCs can simultaneously target two different antigens, enhancing tumor selectivity and reducing off-target effects. This innovative approach holds great promise for improving treatment efficacy in various cancers, offering new hope for patients with limited therapeutic options. As research advances, bispecific ADCs are expected to play a crucial role in the next generation of oncology treatments.